| Identification | Back Directory | [Name]
1H-Pyrazole-4-carboxamide, 1-[(3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridinyl)amino]- | [CAS]
2169273-59-8 | [Synonyms]
Atinvicitinib
1-[(3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridinyl)amino]-1H-Pyrazole-4-carboxamide
1H-Pyrazole-4-carboxamide, 1-[(3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridinyl)amino]- | [Molecular Formula]
C16H17FN6O3 | [MOL File]
2169273-59-8.mol | [Molecular Weight]
360.34 |
| Chemical Properties | Back Directory | [Boiling point ]
623.6±55.0 °C(Predicted) | [density ]
1.53±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
14.99±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Atinvicitinib is a kind of pyrazole compound. Atinvicitinib has the potential for the research of atopic dermatitis (extracted from patent WO2021123094A1)[1]. | [References]
[1] Mohamad Morsey, et al. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis. Patent WO2021123094A1. |
|
|